152 related articles for article (PubMed ID: 22231235)
1. SSc in 2011: From mechanisms to medicines.
Mouthon L
Nat Rev Rheumatol; 2012 Jan; 8(2):72-4. PubMed ID: 22231235
[TBL] [Abstract][Full Text] [Related]
2. Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities.
Iwayama T; Olson LE
Curr Rheumatol Rep; 2013 Feb; 15(2):304. PubMed ID: 23307576
[TBL] [Abstract][Full Text] [Related]
3. Imatinib and the treatment of fibrosis: recent trials and tribulations.
Gordon J; Spiera R
Curr Rheumatol Rep; 2011 Feb; 13(1):51-8. PubMed ID: 21086081
[TBL] [Abstract][Full Text] [Related]
4. [A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].
Taïeb A; Constans J; Mahon FX
Rev Med Interne; 2008 Mar; 29(3):173-5. PubMed ID: 17597261
[No Abstract] [Full Text] [Related]
5. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Beyer C; Distler JH; Distler O
Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
[TBL] [Abstract][Full Text] [Related]
6. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
Pannu J; Asano Y; Nakerakanti S; Smith E; Jablonska S; Blaszczyk M; ten Dijke P; Trojanowska M
Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.
Iwamoto N; Distler JH; Distler O
Curr Rheumatol Rep; 2011 Feb; 13(1):21-7. PubMed ID: 21042889
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
9. Is IL-4 a potential therapeutic target in systemic sclerosis-associated pulmonary fibrosis?
Sfikakis PP
Clin Immunol; 2011 Dec; 141(3):240-1. PubMed ID: 21996458
[No Abstract] [Full Text] [Related]
10. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
Distler JH; Distler O
Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v10-1. PubMed ID: 18784126
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pulmonary fibrosis in systemic sclerosis: light at the end of the tunnel?
Wollheim FA
Arthritis Rheum; 2007 Jan; 56(1):9-12. PubMed ID: 17195185
[No Abstract] [Full Text] [Related]
12. Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases.
Tamaki Z; Asano Y; Hatano M; Yao A; Kawashima T; Tomita M; Kinugawa K; Nagai R; Sato S
Mod Rheumatol; 2012 Feb; 22(1):94-9. PubMed ID: 21633912
[TBL] [Abstract][Full Text] [Related]
13. Is imatinib mesylate a promising drug in systemic sclerosis?
van Daele PL; Dik WA; Thio HB; van Hal PT; van Laar JA; Hooijkaas H; van Hagen PM
Arthritis Rheum; 2008 Aug; 58(8):2549-52. PubMed ID: 18668570
[TBL] [Abstract][Full Text] [Related]
14. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors.
Maurer B; Distler A; Dees C; Khan K; Denton CP; Abraham D; Gay RE; Michel BA; Gay S; Hw Distler J; Distler O
Ann Rheum Dis; 2013 Dec; 72(12):2039-46. PubMed ID: 24013728
[TBL] [Abstract][Full Text] [Related]
15. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.
Au K; Khanna D; Clements PJ; Furst DE; Tashkin DP
Curr Rheumatol Rep; 2009 Apr; 11(2):111-9. PubMed ID: 19296883
[TBL] [Abstract][Full Text] [Related]
16. Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.
Divekar AA; Khanna D; Abtin F; Maranian P; Saggar R; Saggar R; Furst DE; Singh RR
Clin Immunol; 2011 Dec; 141(3):293-303. PubMed ID: 22015344
[TBL] [Abstract][Full Text] [Related]
17. Future treatments in systemic sclerosis.
Asano Y
J Dermatol; 2010 Jan; 37(1):54-70. PubMed ID: 20175840
[TBL] [Abstract][Full Text] [Related]
18. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.
Khanna D; Saggar R; Mayes MD; Abtin F; Clements PJ; Maranian P; Assassi S; Saggar R; Singh RR; Furst DE
Arthritis Rheum; 2011 Nov; 63(11):3540-6. PubMed ID: 21769849
[TBL] [Abstract][Full Text] [Related]
19. Molecular framework for response to imatinib mesylate in systemic sclerosis.
Chung L; Fiorentino DF; Benbarak MJ; Adler AS; Mariano MM; Paniagua RT; Milano A; Connolly MK; Ratiner BD; Wiskocil RL; Whitfield ML; Chang HY; Robinson WH
Arthritis Rheum; 2009 Feb; 60(2):584-91. PubMed ID: 19180499
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?
Mendoza FA; Jiménez SA
Arthritis Rheum; 2011 Nov; 63(11):3199-203. PubMed ID: 21769846
[No Abstract] [Full Text] [Related]
[Next] [New Search]
